Zacks Investment Research lowered shares of Asterias Biotherapeutics (NYSEAMERICAN:AST) from a hold rating to a sell rating in a research report released on Friday morning.
According to Zacks, “Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company’s technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. “
Separately, HC Wainwright reaffirmed a buy rating and issued a $12.00 price objective on shares of Asterias Biotherapeutics in a report on Monday, October 2nd. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $8.94.
Asterias Biotherapeutics (NYSEAMERICAN:AST) last released its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.15) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.15). Asterias Biotherapeutics had a negative net margin of 403.38% and a negative return on equity of 79.80%.
TRADEMARK VIOLATION WARNING: “Asterias Biotherapeutics (AST) Cut to “Sell” at Zacks Investment Research” was published by BBNS and is the property of of BBNS. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://baseballnewssource.com/markets/asterias-biotherapeutics-ast-cut-to-sell-at-zacks-investment-research/1858656.html.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.